Intersect ENT Inc. (NASDAQ:XENT) shares fell 2.2% on Friday . The stock traded as low as $13.03 and last traded at $13.22, with a volume of 139,951 shares trading hands. The stock had previously closed at $13.52.

Several analysts have recently commented on the company. BTIG Research assumed coverage on Intersect ENT in a report on Tuesday. They issued a “neutral” rating for the company. Canaccord Genuity reissued a “buy” rating on shares of Intersect ENT in a report on Thursday, March 24th. Zacks Investment Research raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Leerink Swann reissued a “buy” rating on shares of Intersect ENT in a report on Thursday, March 24th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $29.00 price target on shares of Intersect ENT in a report on Thursday, March 24th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $26.33.

The stock’s market capitalization is $391.47 million. The stock has a 50-day moving average of $13.52 and a 200 day moving average of $16.78.

Intersect ENT (NASDAQ:XENT) last posted its earnings results on Thursday, May 5th. The company reported ($0.29) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29). The company had revenue of $16.69 million for the quarter, compared to the consensus estimate of $16.92 million. During the same period last year, the company posted ($0.23) earnings per share. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. Equities analysts predict that Intersect ENT Inc. will post ($1.01) EPS for the current year.

In other news, VP Amy Wolbeck sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 27th. The stock was sold at an average price of $20.01, for a total transaction of $40,020.00. Following the completion of the transaction, the vice president now directly owns 7,700 shares of the company’s stock, valued at $154,077. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Lisa D. Earnhardt sold 28,500 shares of the company’s stock in a transaction that occurred on Monday, April 18th. The shares were sold at an average price of $18.69, for a total value of $532,665.00. Following the transaction, the chief executive officer now directly owns 581,368 shares of the company’s stock, valued at $10,865,767.92. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of XENT. Jennison Associates LLC raised its position in Intersect ENT by 11.2% in the fourth quarter. Jennison Associates LLC now owns 2,770,905 shares of the company’s stock valued at $62,345,000 after buying an additional 279,176 shares during the period. Wells Fargo & Company MN raised its position in shares of Intersect ENT by 36.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,288,725 shares of the company’s stock worth $51,495,000 after buying an additional 607,788 shares during the period. Royce & Associates LLC raised its position in shares of Intersect ENT by 15.7% in the fourth quarter. Royce & Associates LLC now owns 420,400 shares of the company’s stock worth $9,459,000 after buying an additional 56,900 shares during the period. Schroder Investment Management Group acquired a new position in shares of Intersect ENT during the fourth quarter worth about $6,845,000. Finally, Tamarack Advisers LP acquired a new position in shares of Intersect ENT during the fourth quarter worth about $5,609,000.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.